6609 Stock Overview
Researches, develops, manufacture, and sells neuro-interventional medical devices in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6609 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Shanghai HeartCare Medical Technology Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$24.35 |
| 52 Week High | HK$26.80 |
| 52 Week Low | HK$12.10 |
| Beta | 0.67 |
| 1 Month Change | 7.98% |
| 3 Month Change | 21.87% |
| 1 Year Change | 14.59% |
| 3 Year Change | -66.13% |
| 5 Year Change | n/a |
| Change since IPO | -81.12% |
Recent News & Updates
Even With A 42% Surge, Cautious Investors Are Not Rewarding Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Performance Completely
Sep 27
Some Shareholders Feeling Restless Over Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) P/S Ratio
Aug 01Recent updates
Even With A 42% Surge, Cautious Investors Are Not Rewarding Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Performance Completely
Sep 27Some Shareholders Feeling Restless Over Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) P/S Ratio
Aug 01We're Not Very Worried About Shanghai HeartCare Medical Technology's (HKG:6609) Cash Burn Rate
Jan 23Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Aug 30Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth
Aug 09Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth
May 07We're Hopeful That Shanghai HeartCare Medical Technology (HKG:6609) Will Use Its Cash Wisely
Nov 29Shareholder Returns
| 6609 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 16.5% | 2.3% | 1.2% |
| 1Y | 14.6% | -16.1% | 20.6% |
Return vs Industry: 6609 exceeded the Hong Kong Medical Equipment industry which returned -16.1% over the past year.
Return vs Market: 6609 underperformed the Hong Kong Market which returned 20.6% over the past year.
Price Volatility
| 6609 volatility | |
|---|---|
| 6609 Average Weekly Movement | 6.9% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 6609 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6609's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 341 | Guohui Wang | www.heartcare.com.cn |
Shanghai HeartCare Medical Technology Corporation Limited researches, develops, manufacture, and sells neuro-interventional medical devices in Mainland China. The company offers ischemic stroke thrombectomy devices, such as Captor thrombectomy device, and aspiration catheter and pump; intracranial stenosis treatment devices comprising intracranial drug-eluting balloon catheter and embolization protection system; hemorrhagic stroke treatment devices, including coil embolization assistant stent and flow diverter device; and ischemic stroke prevention devices, such as LAA occlude. It also provides vascular access devices comprising distal access catheter, microcatheter, balloon guiding catheter, vascular closure device, support catheter, neuro-interventional microcatheter, micro guidewire, microcatheter for coiling, microcatheter for flow diverter device, and navigation catheter.
Shanghai HeartCare Medical Technology Corporation Limited Fundamentals Summary
| 6609 fundamental statistics | |
|---|---|
| Market cap | HK$928.74m |
| Earnings (TTM) | -HK$47.88m |
| Revenue (TTM) | HK$268.56m |
3.5x
P/S Ratio-19.4x
P/E RatioIs 6609 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6609 income statement (TTM) | |
|---|---|
| Revenue | CN¥251.24m |
| Cost of Revenue | CN¥96.89m |
| Gross Profit | CN¥154.36m |
| Other Expenses | CN¥199.15m |
| Earnings | -CN¥44.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 61.44% |
| Net Profit Margin | -17.83% |
| Debt/Equity Ratio | 0% |
How did 6609 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/23 01:33 |
| End of Day Share Price | 2025/01/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai HeartCare Medical Technology Corporation Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Yuan Gao | China International Capital Corporation Limited |
| Chris Pan | Goldman Sachs |